Coronavirus COVID-19 Outbreak – What's New

William M. Detmer, MD, supported by the Unbound Medicine Team

Updated: Monday, November 23, 2020 10:43 ET

COVID-19 Cases

Around the Globe

New Cases in Countries with Highest COVID-19 Activity
New Cases in Countries with Highest COVID-19 Activity

Recent Confirmed Cases in countries with the highest reported COVID-19 activity (India, United States, Brazil, Argentina, Colombia, France, Peru, Mexico, Russia, UK). Note that the left axis is linear rather than logarithmic and representsthe number of cases reported (rolling 3-day average) to the European CDC by each country.

Click for Live Updates.

Data sources: European CDC. Our World in Data.

Total and New COVID-19 Cases — from European CDC

Cases

Deaths

November 23, 2020

Total

New

Total

New

United States

12,246,909

157,471

256,782

883

India

9,139,865

44,059

133,738

511

Italy

1,408,868

28,337

49,823

562

Russia

2,114,502

25,173

36,540

361

United_Kingdom

1,512,045

18,662

54,751

125

Brazil

6,071,401

18,615

169,183

194

Poland

861,331

17,856

13,618

330

France

2,140,208

13,157

48,732

214

Iran

854,361

13,053

44,802

475

Germany

929,133

10,864

14,112

90

Mexico

1,041,875

9,187

101,676

303

Colombia

1,248,417

7,924

35,287

183

Turkey

446,822

6,017

12,358

139

Romania

418,645

5,837

10,047

131

Netherlands

484,060

5,382

8,879

21

Other countries

17,848,701

108,292

398,333

1,990

TOTAL

58,767,143

489,886

1,388,661

6,512

European Centre for Disease Prevention and Control.[1]

Note: ECDC statistics are reported daily. See other sources for hour-by-hour updates.

Statistics may differ from other reporting agencies.

COVID-19 Outbreak Map by Johns Hopkins CSSE – Updated Hourly
Coronavirus 2019 COVID-19 Outbreak Map

Click one of the links below to see the latest.
Desktop | Mobile
Source: Johns Hopkins Center for Systems Science and Engineering (CSSE).[2]

In the United States

  • As of November 22 12:15 ET (CDC)
    • Total cases: more than 12.0 million in all 50 states
    • Deaths: more than 255,000 reported
U.S. Key COVID-19 Metrics: November 23
U.S. Key COVID-19 Metrics - What's New

Key COVID-19 metrics in the United States since April 1. Dark lines represent 7-day averages.

Click for Live Updates.

Source: The COVID-19 Tracking Project[3]

U.S. Deaths and Cases by State and County
Coronavirus deaths in US by State and County

Aggregate data from the Centers for Disease Control and Prevention (CDC) and state- and local-level public health agencies. County-level data is confirmed by referencing state and local agencies directly. Confirmed cases and deaths reflect cumulative totals since January 22nd, 2020.

Click for Live Updates.

Source: USAFacts.org.[4]

U.S. States with the Most COVID-19 Activity

Cases

Deaths

State

Total

Last 7d

Per 100k

Total

Last 7d

Per 100k

Illinois

646,286

83,301

5,072

11,952

864

70

California

1,087,714

79,337

2,750

18,643

425

77

Texas

1,085,524

71,364

3,782

20,467

997

0

Florida

918,240

55,250

4,311

17,930

441

90

Michigan

329,021

53,229

3,294

8,875

499

47

Ohio

343,286

53,043

2,937

5,984

270

48

Wisconsin

372,219

48,615

6,403

3,143

404

135

Minnesota

262,952

46,924

4,686

3,257

327

95

Indiana

289,183

44,296

4,321

5,246

358

77

Pennsylvania

302,564

42,626

2,362

9,801

527

84

Colorado

194,679

35,445

3,418

2,787

262

0

Missouri

271,527

32,076

4,432

3,559

185

87

Tennessee

335,887

30,767

4,961

4,211

334

62

New Jersey

302,039

27,303

3,390

16,746

198

16

Iowa

207,675

26,343

6,580

2,160

187

68

Oklahoma

182,593

24,142

4,631

1,659

122

48

Georgia

446,804

23,899

4,247

9,179

223

93

North Carolina

332,261

23,143

3,200

5,005

249

78

Utah

173,979

22,838

5,504

787

77

48

Arizona

295,334

22,281

4,118

6,457

157

39

New York

297,988

22,036

2,674

9,652

180

133

Kentucky

155,908

19,771

3,489

1,783

125

151

Kansas

134,533

19,026

4,621

1,410

151

73

Massachusetts

207,225

16,861

3,002

10,465

192

13

New Mexico

79,440

16,269

3,791

1,350

142

88

Maryland

182,139

16,209

3,014

4,434

132

58

Nebraska

113,029

16,195

5,859

905

126

58

Virginia

217,797

15,836

2,557

3,938

138

3

Alabama

230,708

14,865

4,720

3,457

211

123

Louisiana

216,709

14,728

4,650

6,233

112

56

Washington

141,260

13,529

1,875

2,619

100

48

Connecticut

101,469

12,824

2,840

4,828

91

110

Nevada

131,733

12,727

4,341

2,011

103

46

New York City

296,450

12,215

3,530

24,207

82

37

Arkansas

143,821

11,655

4,772

2,337

178

187

South Carolina

205,018

11,004

4,032

4,274

164

64

U.S. Centers for Disease Control.

What’s New Elsewhere

Feedback

Your feedback is appreciated!

Share this page

Share by emailShare by FacebookShare by Twitter

References

  1. Situation update worldwide. European Centre for Disease Prevention and Control. [https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases]
  2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020.  [PMID:32087114]
  3. Nationwide COVID-19 Metrics Since April 1. The COVID Tracking Project. [https://covidtracking.com/data/charts/us-all-key-metrics]
  4. Coronavirus Locations: COVID-19 Map by County and State. USAFacts.org. [https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/]
  5. Abbasi J. The Promise and Peril of Antibody Testing for COVID-19. JAMA. 2020.  [PMID:32301958]
  6. Angulo FJ, Finelli L, Swerdlow DL. Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level. JAMA. 2020.  [PMID:32412582]
  7. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996.  [PMID:32471884]
  8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020.  [PMID:32445440]
  9. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020.  [PMID:32412710]
  10. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020.  [PMID:32492293]
  11. Brooks JT, Butler JC, Redfield RR. Universal Masking to Prevent SARS-CoV-2 Transmission-The Time Is Now. JAMA. 2020.  [PMID:32663243]
  12. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 27 June 2020.
  13. Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020.  [PMID:32644129]
  14. Cavalcanti AB et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. July 23, 2020 DOI: 10.1056/NEJMoa2019014
  15. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020.  [PMID:32434946]
  16. Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020.  [PMID:32219057]
  17. Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020.  [PMID:32497510]
  18. Coronavirus Disease 2019 (COVID-19) Situation Reports. World Health Organization. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-...]
  19. Coronavirus in the U.S.: Latest Map and Case Count. New York Times. [https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html]
  20. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020.  [PMID:32598830]
  21. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020.  [PMID:32558485]
  22. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020.  [PMID:32598831]
  23. Gao Q, Bao L, Mao H, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020.  [PMID:32376603]
  24. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020.  [PMID:32379955]
  25. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020.  [PMID:32459919]
  26. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020.  [PMID:32275812]
  27. Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med. 2020.  [PMID:32402157]
  28. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020.  [PMID:32692365]
  29. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020.  [PMID:32401715]
  30. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020.  [PMID:32663912]
  31. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. JAMA. 2020.  [PMID:32391855]
  32. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412-1413.  [PMID:32217705]
  33. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020.  [PMID:32492084]
  34. Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020.  [PMID:32227757]
  35. Mahase E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ. 2020;369:m2422.  [PMID:32546467]
  36. Mahase E. Covid-19: What is the evidence for cloth masks? BMJ. 2020;369:m1422.  [PMID:32265341]
  37. Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.  [PMID:32450107]
  38. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020.  [PMID:32303591]
  39. Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis. 2020.  [PMID:32628269]
  40. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 [News]. US National Institute of Allergy and Infectious Diseases. April 29, 2020. [https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-...]
  41. NIH clinical trial of investigational vaccine for COVID-19 begins: study enrolling Seattle-based healthy adult volunteers [News]. March 16, 2020. [https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investiga...]
  42. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. Lancet. 2020;395(10236):1525-1527.  [PMID:32423580]
  43. Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395(10230):1101-1102.  [PMID:32247384]
  44. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020.  [PMID:32645347]
  45. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.  [PMID:32678530]
  46. Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. U.S. Centers for Disease Control and Prevention. [https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-...]
  47. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020.  [PMID:32392282]
  48. Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. JAMA. 2020.  [PMID:32421155]
  49. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020.  [PMID:32374370]
  50. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020.  [PMID:32269068]
  51. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med. 2020.  [PMID:32673060]
  52. Stringhini S et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. June 11, 2020. S0140-6736(20)31304-0. [https://doi.org/10.1016/]
  53. Studdert DM, Hall MA. Disease Control, Civil Liberties, and Mass Testing - Calibrating Restrictions during the Covid-19 Pandemic. N Engl J Med. 2020.  [PMID:32272003]
  54. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.  [PMID:32409561]
  55. Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ. 2020;369:m2263.  [PMID:32513810]
  56. Treon SP, Castillo J, Skarbnik AP, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood. 2020.  [PMID:32302379]
  57. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020.  [PMID:32410760]
  58. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020.  [PMID:32532802]
  59. Wang X, Ferro EG, Zhou G, et al. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA. 2020.  [PMID:32663246]
  60. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578.  [PMID:32423584]
  61. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020.  [PMID:32648899]
  62. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med. 2020.  [PMID:32502334]

Coronavirus COVID-19 Outbreak – What's Newis the Relief Central Word of the day!

Last updated: November 23, 2020